Stock overview
Eli Lilly & Co.
Explore the company, reported ownership, price history, and available source evidence.
Eli Lilly develops medicines for diabetes, obesity, oncology, immunology, and neuroscience.
- Last close
- $1183.46
- · LLY
- Tracked holders
- 8 funds
- Latest available 13F per fund
LLY · USD
Price
Close · Sep 25, 2026
- Range low
- $221.60
- Range high
- $1,280.34
- Observations
- 1255
- Session date
- Sep 25, 2026
Sep 27, 2021–Sep 25, 2026. Regular market hours only. Historical prices are unadjusted; splits and other corporate actions can affect comparisons.
Investor Popularity
Rows are narrowed by movement, fund type, and position size.
| Fund | Move | Value | Weight |
|---|---|---|---|
| Polen Capital Management largest tracked holder Q2 2026 · filed Aug 4, 2026 · SEC filing | −27% 26'Q2 | $799,914,391 | 6.89% |
| ARK Investment Management position history Q2 2026 · filed Aug 14, 2026 · SEC filing | +510% 26'Q2 | $92,660,897 | 0.6% |
| Samlyn Capital position history Q2 2026 · filed Aug 14, 2026 · SEC filing | −48% 26'Q2 | $44,528,840 | 0.72% |
| Tudor Investment Corp position history Q2 2026 · filed Aug 14, 2026 · SEC filing | −75% 26'Q2 | $37,044,396 | 0.05% |
| Renaissance Technologies position history Q2 2026 · filed Aug 13, 2026 · SEC filing | −64% 26'Q2 | $31,294,701 | 0.04% |
| Gotham Asset Management position history Q2 2026 · filed Aug 14, 2026 · SEC filing | +36% 26'Q2 | $26,352,677 | 0.06% |
| Duquesne Family Office position history Q2 2026 · filed Aug 14, 2026 · SEC filing | Newly reported 26'Q2 | $14,849,000 | 0.28% |
|
Thrive Capital
position history
Q2 2026
· filed Aug 14, 2026
· SEC filing 1 SEC filing 2 |
+11% 26'Q2 | $5,224,135 | 0.12% |
SEC Forms 4/5
Insiders
Financials
Official-source analysis
AI Earnings Report
No published AI Earnings Report yet
We publish a cited AI Earnings Report after an eligible official earnings filing is accepted and passes validation.
Options market